A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS –FLI1 fusion transcript

ConclusionsHepatotoxicity precluded the administration of a mithramycin at a dose required to inhibit EWS –FLI1. Evaluation of mithramycin in patients selected for decreased susceptibility to elevated transaminases may allow for improved drug exposure. (Source: Cancer Chemotherapy and Pharmacology)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2gSMdNw
via IFTTT